Media Q&A covering Nuclera’s CEO appointment, leadership transition, commercial growth strategy, and priorities for the next phase of the company’s development.
- Address Here
- Email Address Here
Media Q&A covering Nuclera’s CEO appointment, leadership transition, commercial growth strategy, and priorities for the next phase of the company’s development.
Funding will accelerate commercialization of Elucid’s AI-powered cardiovascular imaging platform and expand strategic partnerships with leading medical technology companies. BOSTON — Sept. 2, 2026 — Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, today announced the raise of $55 million in an oversubscribed Series D […]
The First Uniform 0.024” Diameter Wire, Purpose-Built for Stroke Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation neurovascular guidewire purposebuilt to improve vascular access during stroke procedures. “Advances in aspiration thrombectomy over the past […]
Funding supports continued growth and innovation in thromboembolic disease care. Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the closing of an oversubscribed $100 million convertible note financing. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors in partnership with […]
Category I CPT® Code Granted for an Implantable Shock Absorber for Knee Osteoarthritis. The Arthroscopy Association of North America (AANA), an international professional organization of more than 5,000 orthopedic surgeons, today announced an important milestone to expand access for knee osteoarthritis (OA) patients. The American Medical Association (AMA) CPT Editorial Panel has established a Category […]
Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension, announced today the closing of a $50 million Series B equity financing. The time has arrived to make ABPM a true standard of care. Biobeat secures $50M to […]
SetPoint Medical is offering patients with the autoimmune disorder rheumatoid arthritis something close to a cure. The company’s SetPoint System—which was FDA approved in July—is a small neck implant that gives an electrical jolt for one minute a day to the vagus nerve, and has been shown to help regulate the body’s immune response. “This […]
Sofinnova Partners leads premier investor syndicate backing Galvanize’s breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD. Galvanize (“Galvanize”) Therapeutics, Inc, a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease successfully raised an oversubscribed $100 million Series C […]
The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease. The Food and Drug Administration on Wednesday approved a medical device that offers new hope to patients incapacitated by rheumatoid arthritis, a chronic condition that afflicts 1.5 million Americans and is often resistant to treatment. The […]
VALENCIA, Calif.–(BUSINESS WIRE)–SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced that it has raised $140 million in private financing, that includes $25 million in the second tranche of its Series C financing, as well as $115 million in its Series D financing, co-led by Elevage Medical Technologies […]
FDA awards Breakthrough Device Designation to FIRE1’s Norm™ system DUBLIN–FIRE1, a leading connected medical device solutions company, today announced the successful completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. FIRE1’s Norm™ heart failure management system offers a groundbreaking approach […]
This Announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No. 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended (“EUWA“) and as it may be modified from time to time by or under domestic law including, but not limited to, by the Market Abuse (Amendment) (EU […]